论文部分内容阅读
本文应用HBAg-iRNA穴位注射(穴注)与肝必复口服治疗慢性乙型肝炎(慢乙肝)100例,治前HBsAg、HBeAg、抗-HBc均阳性,抗-HBs、抗-HBe均阴性,多数SGPT异常,三个月为一疗程,疗程结束及治后一年复查上述指标。结果显示两组近期疗效分别为:HBeAg转阴50%、18%,抗-HBe转阳46%、18%,HBsAg滴度显降48%、16%,抗-HBc下降32%、2%,临床症状体征改善90%、36%,均以HBAg-iRNA为佳(P<0.05);远期疗效分别为:HBeAg转阴52%、14.63%,抗-HBe转阳48%、14.63%,HBsAg转阴或显降为72%、14.63%,抗-HBs转阳6%、0%,抗-HBc转阴12%、0%,SGPT恢复正常82%、58.54%,亦以HBAg-iRNA为优(P<0.05)。
In this paper, 100 cases of chronic hepatitis B (chronic hepatitis B) were treated with HBAg-iRNA acupoint injection (point injection) and Ganbifu orally, all of which were positive for HBsAg, HBeAg and anti-HBc, negative for anti-HBs and anti- Most SGPT abnormalities, three months for a course of treatment, the end of treatment and review of the above indicators one year after treatment. The results showed that the short-term curative effect of the two groups were: 50%, 18% of HBeAg negative conversion, 46%, 18% HBsAg positive, the HBsAg titer decreased 48%, 16%, anti-HBc decreased 32% The clinical symptoms and signs improved by 90% and 36%, respectively, with HBAg-iRNA being better (P <0.05). The long-term effects were: HBeAg negative 52%, 14.63%, anti-HBe positive 48%, 14.63% Negative or decreased to 72%, 14.63%, anti-HBs positive 6%, 0%, anti-HBc negative 12%, 0%, SGPT returned to normal 82%, 58.54%, also HBAg-iRNA is excellent (P <0.05).